116 related articles for article (PubMed ID: 24083818)
21. Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?
Marin D
J Clin Oncol; 2014 Feb; 32(5):379-84. PubMed ID: 24419129
[No Abstract] [Full Text] [Related]
22. Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.
Stella S; Tirró E; Massimino M; Vitale SR; Russo S; Pennisi MS; Puma A; Romano C; DI Gregorio S; Innao V; Stagno F; DI Raimondo F; Musolino C; Manzella L
In Vivo; 2019; 33(5):1593-1598. PubMed ID: 31471409
[TBL] [Abstract][Full Text] [Related]
23. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
[No Abstract] [Full Text] [Related]
24. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
25. Generic Imatinib in Chronic Myeloid Leukemia Treatment: Long-Term Follow-up.
Ćojbašić I; Mačukanović-Golubović L; Vučić M; Ćojbašić Ž
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e526-e531. PubMed ID: 31239209
[TBL] [Abstract][Full Text] [Related]
26. Imatinib resistance in chronic myeloid leukemia due to a rare mutation.
Balasubramanian P; Chopra A; Verma D; Singh IK; Kumar A; Sharma A; Kumar R
Leuk Lymphoma; 2017 Jul; 58(7):1750-1752. PubMed ID: 27868464
[No Abstract] [Full Text] [Related]
27. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Stagno F; Iurlo A; Albano F; Abruzzese E; Martino B; Levato L; Intermesoli T; Pregno P; Rossi G; Gherlinzoni F; Leoni P; Cavazzini F; Venturi C; Soverini S; Testoni N; Alimena G; Cavo M; Martinelli G; Pane F; Saglio G; Rosti G; Baccarani M;
Leukemia; 2015 Sep; 29(9):1823-31. PubMed ID: 26088952
[TBL] [Abstract][Full Text] [Related]
28. Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India.
Kuila N; Dash N; Sahoo DP; Pattnayak NC; Biswas G; Chakraborty S
Leuk Lymphoma; 2009 Apr; 50(4):663-6. PubMed ID: 19373669
[No Abstract] [Full Text] [Related]
29. Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.
Proschmann R; Baldow C; Rothe T; Suttorp M; Thiede C; Tauer JT; Müller MC; Hochhaus A; Roeder I; Glauche I
Haematologica; 2017 Feb; 102(2):e39-e42. PubMed ID: 27856510
[No Abstract] [Full Text] [Related]
30. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M
Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053
[No Abstract] [Full Text] [Related]
31. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
Etienne G; Guilhot J; Rea D; Rigal-Huguet F; Nicolini F; Charbonnier A; Guerci-Bresler A; Legros L; Varet B; Gardembas M; Dubruille V; Tulliez M; Noel MP; Ianotto JC; Villemagne B; Carré M; Guilhot F; Rousselot P; Mahon FX
J Clin Oncol; 2017 Jan; 35(3):298-305. PubMed ID: 28095277
[TBL] [Abstract][Full Text] [Related]
32. miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
Ramachandran SS; Muiwo P; Ahmad HM; Pandey RM; Singh S; Bakhshi S; Kumar L; Bhattacharya A; Gupta YK
Leuk Lymphoma; 2017 Aug; 58(8):1981-1984. PubMed ID: 28093001
[No Abstract] [Full Text] [Related]
33. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
34. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
Vatel O; Aumont C; Mathy V; Petit M; Feriel J; Sloma I; Bennaceur-Griscelli A; Turhan AG
Leuk Lymphoma; 2017 Feb; 58(2):473-474. PubMed ID: 27389710
[No Abstract] [Full Text] [Related]
35. Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.
Molica M; Breccia M; Colafigli G; Massaro F; Quattrocchi L; Mancini M; Diverio D; Latagliata R; Foà R
Br J Haematol; 2018 Apr; 181(2):275-278. PubMed ID: 28211562
[No Abstract] [Full Text] [Related]
36. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
37. Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.
Chahardouli B; Zaker F; Mousavi SA; Saffari Z; Nadali F; Ostadali M; Ghadimi H; Alimoghaddam K; Ghavamzade A; Rostami S
Hematology; 2013 Nov; 18(6):328-33. PubMed ID: 23676790
[TBL] [Abstract][Full Text] [Related]
38. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
[TBL] [Abstract][Full Text] [Related]
39. The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial.
Austin GM; Knight K; Bell J; Carter A; Heartin E; Watson D; Foroni L; Christmas SE; Polydoros F; Clark RE
Br J Haematol; 2019 May; 185(4):791-793. PubMed ID: 30408160
[No Abstract] [Full Text] [Related]
40. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]